FY2022 Earnings Estimate for Innate Pharma S.A. Issued By SVB Leerink (NASDAQ:IPHA)

Innate Pharma S.A. (NASDAQ:IPHAGet Rating) – Investment analysts at SVB Leerink boosted their FY2022 earnings estimates for Innate Pharma in a report issued on Tuesday, August 2nd. SVB Leerink analyst D. Graybosch now expects that the company will post earnings of $0.20 per share for the year, up from their previous forecast of $0.01. SVB Leerink currently has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.38) per share. SVB Leerink also issued estimates for Innate Pharma’s FY2023 earnings at ($0.21) EPS, FY2024 earnings at $0.04 EPS, FY2025 earnings at ($0.19) EPS and FY2026 earnings at $0.68 EPS.

Separately, Kepler Capital Markets lowered shares of Innate Pharma from a “buy” rating to a “hold” rating and set a €3.10 ($3.20) price target on the stock. in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.72.

Innate Pharma Price Performance

Innate Pharma stock opened at $2.76 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.73 and a quick ratio of 1.73. The firm has a 50 day moving average price of $2.80 and a 200-day moving average price of $3.11. Innate Pharma has a twelve month low of $2.00 and a twelve month high of $11.95.

Hedge Funds Weigh In On Innate Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC raised its position in Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock worth $127,000 after acquiring an additional 23,012 shares in the last quarter. Alps Advisors Inc. acquired a new stake in Innate Pharma during the 4th quarter valued at approximately $429,000. Finally, BlackRock Inc. boosted its position in Innate Pharma by 27.4% during the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after purchasing an additional 108,335 shares during the period. 1.74% of the stock is owned by institutional investors and hedge funds.

Innate Pharma Company Profile

(Get Rating)

Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s├ęzary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers.

Featured Articles

Earnings History and Estimates for Innate Pharma (NASDAQ:IPHA)

Want More Great Investing Ideas?

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.